New Edge Advisors, LLC Biomarin Pharmaceutical Inc Transaction History

New Edge Advisors, LLC

$11.2 Billion
Q1 2024

A detailed history of New Edge Advisors, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, New Edge Advisors, LLC holds 270 shares of BMRN stock, worth $22,229. This represents 0.0% of its overall portfolio holdings.

Number of Shares

270

Previous 306 11.76%

Holding current value

$22,229

Previous $29,000 20.69%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$83.81 - $99.0 $3,017 - $3,564	-36 Reduced 11.76%	270 $23,000
Q4 2023 Feb 13, 2024	BUY	$76.22 - $98.51 $10,213 - $13,200	134 Added 77.91%	306 $29,000
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $1,190 - $1,322	-14 Reduced 7.53%	172 $15,000
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $39,179 - $45,335	-452 Reduced 70.85%	186 $16,000
Q1 2023 May 12, 2023	SELL	$87.74 - $117.27 $28,603 - $38,230	-326 Reduced 33.82%	638 $62,000

Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $78,016 - $104,719	964 New	964 $99,000
Q4 2021 Feb 17, 2022	SELL	$71.72 - $91.47 $454,202 - $579,279	-6,333 Closed	0 $0
Q3 2021 Oct 29, 2021	SELL	$74.77 - $85.47 $1,719 - $1,965	-23 Reduced 0.36%	6,333 $489,000
Q2 2021 Jul 22, 2021	BUY	$75.51 - $84.79 $10,495 - $11,785	139 Added 2.24%	6,356 $530,000
Q1 2021 Apr 26, 2021	BUY	$74.73 - $90.69 $7,473 - $9,069	100 Added 1.63%	6,217 $469,000
Q4 2020 Jan 27, 2021	BUY	$72.61 - $90.2 $186,317 - $231,453	2,566 Added 72.26%	6,117 $536,000
Q3 2020 Nov 03, 2020	BUY	$71.87 - $131.03 $79,631 - $145,181	1,108 Added 45.35%	3,551 $270,000
Q2 2020 Jul 29, 2020	BUY	$79.55 - $124.22 $194,340 - $303,469	2,443 New	2,443 $301,000

Others Institutions Holding BMRN

# of Institutions

623

Shares Held

181M

Call Options Held

1.73M

Put Options Held

1.73M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.

Account

New Edge Advisors, LLC Biomarin Pharmaceutical Inc Transaction History